Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ESTA
ESTA logo

ESTA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
72.550
Open
71.120
VWAP
71.26
Vol
747.26K
Mkt Cap
2.06B
Low
70.250
Amount
53.25M
EV/EBITDA(TTM)
--
Total Shares
29.38M
EV
2.24B
EV/OCF(TTM)
--
P/S(TTM)
9.80
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
Show More

Events Timeline

(ET)
2026-04-30
09:00:00
Establishment Labs Secures $300M Loan Facility
select
2026-04-17 (ET)
2026-04-17
16:00:00
Asana Short Interest Soars to 33%
select
2026-04-07 (ET)
2026-04-07
08:10:00
Establishment Labs Surpasses 5 Million Motiva Devices
select

News

seekingalpha
8.5
04-30seekingalpha
Establishment Labs Secures $300M Loan for Refinancing and Growth
  • Financing Structure Optimization: Establishment Labs has entered into a $300 million senior secured term loan with Oaktree Capital Management, split into $265 million for refinancing and $35 million for growth capital, significantly enhancing the company's financial flexibility.
  • Debt Maturity Extension: The loan extends the maturity to 2031 and features a fixed interest rate with potential reductions linked to leverage targets, further strengthening the company's financial stability and future expansion capabilities.
  • Cash Flow Expectations: This loan agreement is expected to support positive free cash flow in the second half of 2026, indicating the company's financial health and growth potential in the future.
  • Revenue Growth Target: Establishment Labs aims for at least 25% revenue growth in 2026 while expanding its minimally invasive platforms, reflecting the company's proactive strategy in its transition towards profitable scale.
Fool
5.0
04-21Fool
Establishment Labs Insider Sells 37,500 Shares Amid Strong Growth
  • Transaction Overview: On April 14, 2026, Establishment Labs Director Juan Jose Chacon Quiros sold 37,500 shares through an indirect market transaction valued at $2.45 million, indicating routine liquidity management under a pre-arranged Rule 10b5-1 plan.
  • Ownership Changes: Post-transaction, Chacon Quiros retains 45,193 shares directly and 1,182,504 shares indirectly, reflecting a 3% reduction in indirect holdings while direct ownership remains unchanged, suggesting continued confidence in the company.
  • Market Performance: The shares were sold at $65.23 each, with Establishment Labs experiencing a 128.09% price increase over the past year, highlighting the company's robust growth potential in the medical device sector.
  • Financial Health: The company reported a 45% year-over-year revenue increase in Q4, reaching $64.6 million, with total annual revenue of $211.1 million, and management projects over 25% growth in 2026, indicating sustained market demand and improving profitability.
moomoo
5.0
03-23moomoo
Director of Establishment Labs (ESTA.US) Proposes Sale of $20.67 Million in Common Stocks via Form 144
  • Stock Sale Announcement: Establishment Labs' Director Juan Jose Chacon Quiros plans to sell 330,000 shares of its common stock.

  • Market Value: The total market value of the shares being sold is approximately $20.67 million.

Fool
6.5
03-09Fool
Rice Hall James Increases Stake in QuidelOrtho
  • Share Increase: Rice Hall James & Associates acquired 574,877 shares of QuidelOrtho in Q4 2026, reflecting confidence in the company's future prospects despite a 43.4% decline in stock price over the past year.
  • Investment Value: This acquisition raised QuidelOrtho's stake to 1.3% of the fund's 13F reportable assets, indicating recognition of its potential value, which may attract further investor interest.
  • Market Performance: As of February 13, 2026, QuidelOrtho's market capitalization stood at $1.6 billion with a current price of $23.58, trailing the S&P 500 by 55.2 percentage points, highlighting competitive pressures in the market.
  • Strategic Adjustments: QuidelOrtho is undergoing strategic adjustments, including strengthening its product pipeline and improving spending returns, with analysts expecting these efforts to yield modest revenue and operating profit growth in the coming years.
NASDAQ.COM
8.5
03-09NASDAQ.COM
Rice Hall James Increases Stake in QuidelOrtho
  • Increased Holdings: Rice Hall James purchased 574,877 shares of QuidelOrtho in Q4, raising its total stake to 833,791 shares valued at $23.8 million, reflecting a positive outlook on the company's future prospects.
  • Investment Value Growth: The position's value increased by $16.2 million at quarter-end, indicating a rise in stock price and additional share purchases, suggesting the fund's optimistic view on QuidelOrtho's potential value.
  • Industry Position: As a leader in in vitro diagnostics, QuidelOrtho has struggled with consistent revenue growth and profitability in recent years, but its strategic adjustments and strengthened product pipeline may improve financial performance, attracting value investors.
  • Market Expectations: Analysts expect QuidelOrtho to achieve modest revenue and operating profit growth in the coming years, although the Motley Fool analyst team did not include it in their list of top investment stocks, indicating a divergence in market perceptions of its potential.
Fool
6.5
03-09Fool
Rice Hall James Increases Stake in Stride by 122,430 Shares
  • Share Increase: Rice Hall James & Associates, LLC increased its stake in Stride by 122,430 shares in Q4 2026, bringing its ownership to 1.5%, indicating confidence in Stride's future growth potential.
  • Market Value Fluctuation: Despite the increase, Stride's quarter-end market value fell by $17.7 million, reflecting the impact of stock price movements and additional shares, suggesting market concerns about its short-term performance.
  • Earnings Outlook: During Stride's Q4 earnings call, management reaffirmed full-year revenue guidance while raising adjusted operating income expectations, indicating that the market's negative reaction may have been overstated, presenting a potential undervaluation opportunity.
  • Market Performance: Stride's stock price has dropped 39.5% over the past year and underperformed the S&P 500 by 51.2 percentage points, highlighting challenges in the education market but also providing potential buying opportunities for investors.
Wall Street analysts forecast ESTA stock price to rise
8 Analyst Rating
Wall Street analysts forecast ESTA stock price to rise
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
75.00
Averages
82.88
High
90.00
Current: 0.000
sliders
Low
75.00
Averages
82.88
High
90.00
Citi
Joanne Wuensch
Neutral
downgrade
$74 -> $65
AI Analysis
2026-04-07
Reason
Citi
Joanne Wuensch
Price Target
$74 -> $65
AI Analysis
2026-04-07
downgrade
Neutral
Reason
Citi analyst Joanne Wuensch lowered the firm's price target on Establishment Labs to $65 from $74 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The "walls of worry are high" into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm's top picks are now Edwards Lifesciences and Intuitive Surgical.
Mizuho
Mizuho
Outperform
maintain
$100
2026-03-24
Reason
Mizuho
Mizuho
Price Target
$100
2026-03-24
maintain
Outperform
Reason
Mizuho says Establishment Labs shares are down 28% since February 28, the first day of the U.S.-Iran conflict, which is "unwarranted and overdone." Establishment has pulled back on concerns that rising oil prices will pressure the company's margins and consumer demand, the analyst tells investors in a research note. Mizuho adds that the stock has been weak more recently on "unsubstantiated evidence" of a short report and insider selling from former CEO Jaun Jose Chacon. The firm believes the macro concerns are "well overdone" considering Establishment purchases silicone under forward contracts while demand at the consumer level, particularly for Preserve, "remains robust." Further, no short report was published, and insider selling is part of a planned previously disclosed 10b5-1 plan, contends Mizuho. As such, it views the stock's current weakness as an "attractive entry point into a best-in-class growth story." Mizuho has an Outperform rating on Establishment Labs with a $100 price target. The stock is down 6% to $56.29 in afternoon trading.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ESTA
Unlock Now

Valuation Metrics

The current forward P/E ratio for Establishment Labs Holdings Inc (ESTA.O) is 0.00, compared to its 5-year average forward P/E of -31.76. For a more detailed relative valuation and DCF analysis to assess Establishment Labs Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-31.76
Current PE
0.00
Overvalued PE
-13.43
Undervalued PE
-50.09

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-86.77
Current EV/EBITDA
-149.22
Overvalued EV/EBITDA
40.75
Undervalued EV/EBITDA
-214.30

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.59
Current PS
6.18
Overvalued PS
10.12
Undervalued PS
5.07

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Daytrading Signale andern
Intellectia · 28 candidates
Price: $5.00 - $100.00Relative Vol: >= 1.80Moving Average Relationship: PriceAboveMA20Three Min Rate Of Change: >= 0.7%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ONDS logo
ONDS
Ondas Inc
4.53B
VG logo
VG
Venture Global Inc
27.96B
SOUN logo
SOUN
SoundHound AI Inc
3.63B
VIAV logo
VIAV
Viavi Solutions Inc
8.18B
NTLA logo
NTLA
Intellia Therapeutics Inc
1.82B
LION logo
LION
Lionsgate Studios Corp
2.61B
create a small cap screener
Intellectia · 1387 candidates
Market Cap Category: small
Ticker
Name
Market Cap$
top bottom
SGRY logo
SGRY
Surgery Partners Inc
2.00B
QDEL logo
QDEL
QuidelOrtho Corp
2.00B
NESR logo
NESR
National Energy Services Reunited Corp
2.00B
DXPE logo
DXPE
DXP Enterprises Inc
2.00B
SKWD logo
SKWD
Skyward Specialty Insurance Group Inc
2.00B
NTCT logo
NTCT
Netscout Systems Inc
2.00B
low cap stocks with a bullish cross
Intellectia · 1029 candidates
Market Cap Category: small, micro, nanoMoving Average Relationship: PriceCrossAboveMA5
Ticker
Name
Market Cap$
top bottom
NTCT logo
NTCT
Netscout Systems Inc
2.00B
NESR logo
NESR
National Energy Services Reunited Corp
2.00B
FMC logo
FMC
FMC Corp
1.99B
VECO logo
VECO
Veeco Instruments Inc
1.99B
CMPR logo
CMPR
Cimpress PLC
1.98B
STC logo
STC
Stewart Information Services Corp
1.98B
what about health tech stocks and robots?
Intellectia · 18 candidates
Market Cap: 50.00M - 50.00BWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ROK logo
ROK
Rockwell Automation Inc
47.26B
SYM logo
SYM
Symbotic Inc
36.98B
TER logo
TER
Teradyne Inc
36.32B
VEEV logo
VEEV
Veeva Systems Inc
36.12B
ZBRA logo
ZBRA
Zebra Technologies Corp
12.31B
DOCS logo
DOCS
Doximity Inc
7.50B

Whales Holding ESTA

S
Summit Partners Public Asset Management, LLC
Holding
ESTA
+34.50%
3M Return
B
Boothbay Fund Management, LLC
Holding
ESTA
+16.38%
3M Return
Q
Qatar Holding LLC
Holding
ESTA
+11.23%
3M Return
N
Nantahala Capital Management, LLC
Holding
ESTA
+10.57%
3M Return
G
Granite Investment Partners, LLC
Holding
ESTA
+9.03%
3M Return
R
Rice Hall James & Associates, LLC
Holding
ESTA
+8.85%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Establishment Labs Holdings Inc (ESTA) stock price today?

The current price of ESTA is 70.99 USD — it has increased 1.07

What is Establishment Labs Holdings Inc (ESTA)'s business?

Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.

What is the price predicton of ESTA Stock?

Wall Street analysts forecast ESTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESTA is82.88 USD with a low forecast of 75.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Establishment Labs Holdings Inc (ESTA)'s revenue for the last quarter?

Establishment Labs Holdings Inc revenue for the last quarter amounts to 64.62M USD, increased 45.16

What is Establishment Labs Holdings Inc (ESTA)'s earnings per share (EPS) for the last quarter?

Establishment Labs Holdings Inc. EPS for the last quarter amounts to -0.09 USD, decreased -92.44

How many employees does Establishment Labs Holdings Inc (ESTA). have?

Establishment Labs Holdings Inc (ESTA) has 1004 emplpoyees as of May 05 2026.

What is Establishment Labs Holdings Inc (ESTA) market cap?

Today ESTA has the market capitalization of 2.06B USD.